View as Webpage

August 14, 2019 from 5:30pm to 8:30pm

Gourmet Food and Cocktails will be served

RSVP Requested:

(Please respond to entry form below)

San Francisco Wine School

·         Directions ·         Website

·         Address: 415 Grand Ave Ste 301, South San Francisco, CA 94080

·         Phone: (650) 763-1324

As the science behind innovations in cell and gene treatments continues to proliferate across more disease states and conditions, life sciences companies are turning the focus to operationalizing and standardizing processes to mitigate variability. As operations begin to scale, there is increased emphasis on safeguarding these therapies through tight logistical timeframes, stringent temperature controls, and precise tracking of identity, custody and condition.

 

For traditional pharmaceutical companies, this move from make-to-stock to make-to-order must drive transformation at both a macro and micro level. Manufacturers are faced with many challenges, however the unique supply chain hurdles in preserving the integrity of cell and gene therapies is considered to be one of the most significant challenges to overcome. Managing and tracing individual orders, facilitating and collaborating more directly with patients, providers, and caregivers, and new pricing models are just a few areas with cascading implications to existing business strategies, processes, roles, and technologies. For start-ups or precommercial companies, the leap from small scale clinical trials to commercialization requires a similarly holistic assessment of the business.